Crohn’s disease: Study on subcutaneous guselkumab (GRAVITI)

ClinicalTrials.gov ID: NCT05197049
Sponsor: Janssen Research & Development, LLC

Official title:
Randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of subcutaneous guselkumab induction therapy in moderately to severely active Crohn’s disease.

Study overview:
Evaluation of the efficacy and safety of guselkumab in patients with Crohn’s disease.